SCHEMBL873976

SCHEMBL873976

COC1(C)CCCCCCCCCCC1

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1928887 1.00
SCHEMBL14365384 1.00 HSD11B1 (0.32) HSD11B1
SCHEMBL14615529 1.00 HSD11B1 (0.32) HSD11B1
SCHEMBL3254625 1.00 HSD11B1 (0.32) HSD11B1
SCHEMBL27514978 1.00 HSD11B1 (0.32) HSD11B1
SCHEMBL13604965 1.00 HSD11B1 (0.32) HSD11B1
SCHEMBL7286427 1.00 HSD11B1 (0.32) HSD11B1
SCHEMBL7280856 1.00 HSD11B1 (0.32) HSD11B1
SCHEMBL2133245 0.97
SCHEMBL6026856 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220364016-A1 PERFUME OIL MIXTURE SYMRISE AG (DE) 2022-11-17 US claimed
EP-4025675-A1 A PERFUME OIL MIXTURE Symrise AG (DE) 2022-07-13 EP claimed
CN-114364773-A Aromatic oil mixture 西姆莱斯股份公司 2022-04-15 CN claimed
EP-3006547-B1 FRAGRANCE-CONTAINING CAPSULE AND COSMETIC IN WHICH SAID CAPSULES ARE BLENDED SHISEIDO CO LTD (JP) 2019-10-30 EP claimed
WO-2018145219-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING SERANI MOSTAZAL JORGE (CL) 2018-08-16 WO claimed
US-20160106637-A1 FRAGRANCE-CONTAINING CAPSULE AND COSMETIC IN WHICH SAID CAPSULES ARE BLENDED SHISEIDO COMPANY, LTD. (JP) 2016-04-21 US claimed
EP-3006547-A1 FRAGRANCE-CONTAINING CAPSULE AND COSMETIC IN WHICH SAID CAPSULES ARE BLENDED Shiseido Company Ltd. (JP) 2016-04-13 EP claimed
US-20100247475-A1 BETA-GLUCURONIDASE INHIBITOR KAO CORPORATION (JP) 2010-09-30 US claimed
EP-2192178-A1 B-GLUCURONIDASE INHIBITOR Kao Corporation (JP) 2010-06-02 EP claimed
WO-1998056337-A1 MALODOR REDUCING COMPOSITION CONTAINING AMBER AND MUSK MATERIALS THE PROCTER & GAMBLE COMPANY (US) 1998-12-17 WO claimed
EP-4136067-B1 ODORANTS AND COMPOSITIONS COMPRISING ODORANTS S H KELKAR AND COMPANY LTD (IN) 2026-04-15 EP disclosed
EP-4025675-B1 A PERFUME OIL MIXTURE SYMRISE AG (DE) 2026-03-18 EP disclosed
US-12545852-B2 Odorants and compositions comprising odorants S H KELKAR AND COMPANY LIMITED (IN) 2026-02-10 US disclosed
EP-3697878-B1 USE OF ODORANTS AND COMPOSITIONS COMPRISING ODORANTS S H KELKAR AND COMPANY LTD (IN) 2026-01-28 EP disclosed
US-12522780-B2 Odorants and compositions comprising odorants S H KELKAR AND COMPANY LIMITED (IN) 2026-01-13 US disclosed
EP-0012246-A1 Aromatic and flavouring substances, their preparation by fermentation, their use and products containing them L. Givaudan & Cie Société Anonyme (CH) 1980-06-25 EP disclosed
US-4198532-A 2,5,7-TIRMETHYL-OCTAN-3-OL OR 6,8-DIMETHYL-NONAN-2-OL GIVAUDAN CORPORATION (US) 1980-04-15 US disclosed
EP-0006616-A1 Tiglic acid ester, process for its preparation, its application and compositions containing it L. Givaudan & Cie Société Anonyme (CH) 1980-01-09 EP disclosed
EP-0003515-A1 Megastigman-4,7-oxides(I) and 7-oxabicyclo(3,3,0)-octanes (II), process for the preparation of (I) and (II), use of (I) and (II) as fragrances and/or flavours, and fragrance and/or flavour compositions containing (I) or (II) L. Givaudan & Cie Société Anonyme (CH) 1979-08-22 EP disclosed
EP-0000719-A2 1,4-Epoxy-trimethyl-butenylidene-cyclohexanes (I), process for their preparation, use of (I) as fragrance and/or flavouring substance, fragrance and/or flavour compositions containing the cyclohexanes L. Givaudan & Cie Société Anonyme (CH) 1979-02-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545852-B2 Odorants and compositions comprising odorants ENY2, CDY1; CDY1B, CHRM5 HSD11B1 1496/4885
US-20100247475-A1 BETA-GLUCURONIDASE INHIBITOR GUSB, GAA, GANAB HSD11B1 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.